Dial Health Drug Supplies Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 9 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 9.50 Cr
as on 05-07-2024
- Revenue %
(FY 2022)
- Profit -80.83%
(FY 2022)
- Ebitda -86.01%
(FY 2022)
- Net Worth -41.98%
(FY 2022)
- Total Assets -99.56%
(FY 2022)
About Dial Health Drug Supplies
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹9.50 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Bhavini Gala, Sandesh Gavhane, and Nirav Sangoi serve as directors at the Company.
- CIN/LLPIN
U51101MH2015PTC270083
- Company No.
270083
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Nov 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Dial Health Drug Supplies?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhavini Gala  | Director | 01-Apr-2017 | Current |
| Sandesh Gavhane | Director | 01-Aug-2019 | Current |
| Nirav Sangoi | Director | 09-Aug-2021 | Current |
Financial Performance of Dial Health Drug Supplies.
Dial Health Drug Supplies Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 80.83% decrease in profit. The company's net worth observed a substantial decline by a decrease of 41.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dial Health Drug Supplies?
In 2020, Dial Health Drug Supplies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avighna Medicare Private LimitedActive 6 years 2 monthsBhavini Gala, Sandesh Gavhane and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 07 Jul 2017 | ₹9.50 Cr | Satisfied |
How Many Employees Work at Dial Health Drug Supplies?
Dial Health Drug Supplies has a workforce of 1 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dial Health Drug Supplies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dial Health Drug Supplies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
